Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Omeros Corporation has received a consensus rating of "Moderate Buy" from eight research firms, with target prices ranging from $20 to $45.
• The company's stock is currently trading at $8.10 and has experienced a 17.6% decline recently, despite having previously reached a 52-week high of $13.60.
• Omeros reported a loss of ($0.53) earnings per share for the last quarter, surpassing analyst expectations while achieving revenue of $28.6 million.

Omeros Corporation (NASDAQ:OMER - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, three have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $27.50.

A number of equities analysts have commented on OMER shares. HC Wainwright lifted their target price on Omeros from $9.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Wednesday. Weiss Ratings restated a "sell (d-)" rating on shares of Omeros in a research note on Wednesday, October 8th. Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Finally, WBB Securities restated a "strong-buy" rating and issued a $45.00 target price on shares of Omeros in a research note on Wednesday.

Omeros Stock Down 17.6%

Shares of Omeros stock opened at $8.10 on Friday. The firm has a market cap of $551.29 million, a P/E ratio of -3.84 and a beta of 2.32. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The business has a 50-day moving average price of $4.57 and a 200 day moving average price of $4.53.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02. The firm had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. As a group, equities research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently made changes to their positions in the business. B. Riley Wealth Advisors Inc. acquired a new position in shares of Omeros during the second quarter worth approximately $32,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Omeros during the second quarter worth approximately $280,000. Tower Research Capital LLC TRC boosted its position in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 11,971 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Omeros by 548.7% during the second quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 21,376 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Omeros during the second quarter worth approximately $316,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.